|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | AstraZeneca Plc (AZN.L), a major pharmaceutical company. |
|---|---|
| Transferring Party | KuDOS Pharmaceuticals, a biotech pharmaceutical firms specializing in cancer therapies based on the inhibition of DNA repair. |
| Sector | Biopharmaceuticals |
| Date | December 22, 2005 |
| Analysis With this $210 million purchase, AZN bolsters its new product pipeline. In 2004, a newly launched AZN lung cancer pill failed to boost survival in a key study. Investors in KuDOS include Advent Venture Partners, BankInvest Biomedical Venture, Euclid SR Partners, Johnson & Johnson Development Corp (JNJ), Life Science Partners, 3i (III.L) and SV Life Sciences. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |